GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1)
analogs, which are used in the treatment of human obesity and diabetes mellitus. The
investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that
may collaborate with GLP-1 analogs to induce the formation of brown fat, which has
anti-diabetic properties. The results will guide future obesity and diabetes mellitus
therapies.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston